ElwynLohMD

PubMed

• Rilotumumab Exposure-Response Relationship in Patients With Advanced or Metastatic Gastric Cancer
  Sameer Doshi, Per Olsson Gisleskog, Yilong Zhang, Min Zhu, Kelly S. Oliner, Elwyn Loh, Juan Jose Perez Ruixo> ;Clinical Cancer Research. 2015 Feb 24
• Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression
  Min Zhu, Rui Tang, Sameer Doshi, Kelly S. Oliner, Sarita Dubey, Yizhou Jiang, Ross C. Donehower, Timothy Iveson, Elwyn Loh, Yilong Zhang> ;British Journal of Cancer. 2015 Feb 3
• Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer.
  Eric Van Cutsem, Cathy Eng, E. Nowara, Anna Swieboda-Sadlej, Niall C. Tebbutt, Edith P. Mitchell, Irina Davidenko, Joe Stephenson, Elena Elez, Hans Prenen, Hongjie Den...> ;Clinical Cancer Research. 2014 Aug 15
• Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label,...
  Timothy Iveson, Ross C. Donehower, Irina Davidenko, Sergey Tjulandin, Andrzej Deptala, Mark Harrison, Somanath Nirni, Kuntegowdanahalli C Lakshmaiah, Anne L. Thomas, Y...> ;Lancet Oncology. 2014 Aug 1
• Population Pharmacokinetics of Rilotumumab, a Fully Human Monoclonal Antibody Against Hepatocyte Growth Factor, in Cancer Patients
  Min Zhu, Sameer Doshi, Per Olsson Gisleskog, Kelly S. Oliner, Juan Jose Perez Ruixo, Elwyn Loh, Yilong Zhang> ;Journal of Pharmaceutical Sciences. 2014 Jan 1
• Differential Pharmacokinetics of Ganitumab in Patients With Metastatic Pancreatic Cancer Versus Other Advanced Solid Cancers
  Min Zhu, Nathalie H. Gosselin, Mita Kuchimanchi, Jessica Johnson, Ian McCaffery, Mohamad‐Samer Mouksassi, Elwyn Loh, Jian-Feng Lu> ;Clinical pharmacology in drug development. 2013 Oct 1
• Putative Predictive Biomarkers of Survival in Patients with Metastatic Pancreatic Adenocarcinoma Treated with Gemcitabine and Ganitumab, an IGF1R Inhibitor
  Ian McCaffery, Yanyan Tudor, Hongjie Deng, Rui Tang, Samuel Suzuki, Sunita Badola, Hedy L. Kindler, Charles S. Fuchs, Elwyn Loh, Scott D. Patterson, Li Chen, Jennifer ...> ;Clinical Cancer Research. 2013 Aug 1
• Ganitumab with either exemestane or fulvestrant for postmenopausal women with advanced, hormone-receptor-positive breast cancer: a randomised, controlled, double-blind...
  John F.R. Robertson, Jean-Marc Ferrero, H Bourgeois, Hagen Kennecke, Richard de Boer, William Jacot, Jesse McGreivy, Samuel Suzuki, Min Zhu, Ian McCaffery, Elwyn Loh, ...> ;Lancet Oncology. 2013 Mar 1
• Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
  Charles J. Ryan, Mark Rosenthal, Siobhan Ng, Joshi J. Alumkal, Joel Picus, Gwenaelle Gravis, Karim Fizazi, Frederic Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Z...> ;Clinical Cancer Research. 2013 Jan 1
• A multicenter, randomized phase II study of rilotumumab (R) (AMG 102) or placebo (Pbo) plus mitoxantrone (M) and prednisone (P) in patients (pts) with previously treat...
  Ryan CJ, Rosenthal M, Ng S, Alumkal JJ, Picus J, Gravis G, Fizazi K, Forget F, Machiels JH, Zhu M, Jiang J, Dubey S, Loh E, Gerritsen WR> ;J. Clin. Oncol.. 2012-02-10
• Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for ganitumab (GAN, AMG 479) in combination with gemcitabine (G) to treat metastatic pancr...
  Lu J, Deng H, Tang R, Hsu C, Kindler HL, Fuchs CS, Gansert JL, Bray S, Suzuki SS, Loh E, Zhu M> ;J. Clin. Oncol.. 2011-05-20
• Effect of baseline (BL) biomarkers on overall survival (OS) in metastatic pancreatic cancer (mPC) patients (pts) treated with ganitumab (GAN; AMG 479) or placebo (P) i...
  McCaffery I, Tudor Y, Deng H, Tang R, Badola S, Kindler HL, Fuchs CS, Loh E, Patterson SD, Chen L, Gansert JL> ;J. Clin. Oncol.. 2011-05-20
• A randomized, phase Ib/II trial of rilotumumab (AMG 102; ril) or ganitumab (AMG 479; gan) with panitumumab (pmab) versus pmab alone in patients (pts) with wild-type (W...
  Eng C, Van Cutsem E, Nowara E, Swieboda-Sadlej A, Tebbutt NC, Mitchell EP, Davidenko I, Oliner K, Chen L, Huang J, McCaffery I, Loh E, Smethurst D, Tabernero J> ;J. Clin. Oncol.. 2011-05-20
• A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
  Patrick Y. Wen, David Schiff, Timothy F. Cloughesy, Jeffrey J. Raizer, John Laterra, Melanie Smitt, Michael Wolf, Kelly S. Oliner, Abraham Anderson, Min Zhu, Elwyn Loh...> ;Neuro-oncology. 2011 Apr 1
• Exposure-response (E-R) analysis to facilitate phase III (P3) dose selection for AMG 479 (A479) in combination with gemcitabine (G) to treat metastatic pancreatic canc...
  Lu J, Deng H, Tang R, Hsu C, Kindler HL, Fuchs C, Gansert J, Bray S, Loh E, Zhu M> ;J. Clin. Oncol.. 2011-02-01
• Join now to see all